Rubin Lab

Titleimage: Rubin Lab

The Rubin lab approach to cancer research has grown in parallel with the rapid expansion of bioinformatics and sequencing technology over the past 10 years.  Our expertise in identifying functional biomarkers and investigating prostate cancer heterogeneity has led to key discoveries in the distinction between indolent and aggressive cancer types.  Our mission is to identify potential therapeutic targets and bridge the latest in cancer genetics research with individual patient oriented clinical care. The Rubin lab is based in Bern at the Department for BioMedical Research (DBMR), University of Bern, Switzerland.

News & Events

20.06.18

Gene Identified that Drives Aggressive Prostate Cancer

An overactive gene appears to cause some prostate cancers to transform from a typical tumor type to a much more aggressive form of the disease, according to new research at Weill Cornell Medicine.

10.10.16

Sequencing Reveals Underpinnings of Aggressive Prostate Cancer Subtype

A subset of treatment-resistant prostate cancer pathologically resembles small cell lung cancer rather than typical prostate cancer, Weill Cornell Medicine and University of Trento investigators discovered in a new study. The scientists say their findings may lead to more effective ways to diagnose and treat neuroendocrine prostate cancer

09.02.16

Vorherige

More News